Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
DALLAS, June 04, 2009 /PRNewswire-FirstCall/ -- announced today that new preclinical efficacy data will shortly be published demonstrating that thiarabine combined with provides much greater antitumor activity than achieved by either agent alone. In one colorectal cancer model, 66% of mice were cured of their tumors. The publication which will appear in the journal was based on work conducted by Access' collaborators at the Southern Research Institute. The paper is entitled (thiarabine). A preprint of the paper is currently available for download from the journal's website.
"Thiarabine is a next generation nucleoside analogue, licensed by Access from ," stated Jeffrey Davis, President & CEO. "Thiarabine has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity. Access is working with leukemia and lymphoma specialists at in Houston to initiate additional Phase 2 clinical trials in , and other indications. Additionally, we are actively seeking co-development partners, and believe that thiarabine could have applications in certain solid tumors as well," he continued.
In the study, thiarabine, clofarabine, and their combinations were tested in five tumor models. "In all cases, thiarabine demonstrated superior tumor growth inhibition than clofarabine when the agents were used alone," commented David P Nowotnik, Ph.D., Access Pharmaceuticals' Senior Vice President, Research and Development. "But, in the combination of these two agents, efficacy was dramatically superior to the use of either agent alone. Tumor regression and cures were observed in several models including colorectal cancer and leukemia. The combination of agents proved to be effective even when used at low doses, indicating a potential for effective treatment with a reduced side-effect profile."
Prior clinical studies have shown that the effectiveness of , or Ara-C, (a close structural analog of thiarabine which is widely used in treating leukemia patients) can be improved by combining it with clofarabine in the treatment of leukemia patients. The Southern Research paper showed that thiarabine/clofarabine combinations have significantly superior efficacy to cytarabine/clofarabine combinations in the xenograft models. Thiarabine has previously been shown to have much better solid tumor efficacy than cytarabine in preclinical models.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at .
CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer,Access Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations, DonaldC. Weinberger or Diana Bittner (media), Wolfe Axelrod, Weinberger Assoc.LLC, +1-212-370-4500
Web site: http://www.accesspharma.com/
Ticker Symbol: (:ACCP.OB),(NASDAQ-OTCBB:ACCP)
Terms and conditions of use apply Copyright © 2009 PR Newswire Association LLC. All rights reserved. A United Business Media Company
Posted: June 2009